OCGN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Ocugen, Inc. Shareholders

New York, New York--(Newsfile Corp. - June 24, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN).

CLICK HERE FOR MORE DETAILS:

https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=17169&from=5

Affected shareholders purchased shares of OCGN between February 2, 2021 and June 10, 2021

Shareholders interested in representing the class of wronged shareholders have until August 17, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Ocugen, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88578